Abstract 1388P
Background
In the last decade, new therapies for NSCLC patients (pts) with specific molecular alterations have emerged. Guidelines now mandate testing pts for these targets. Understanding diagnostics in routine practice is crucial to enhance quality of care.
Methods
The prospective, national clinical research platform CRISP recruits pts in representative cancer centres in all therapeutic sectors in Germany since 2016. More than 10.000 pts were recruited and followed for up to 5 years. Data on molecular testing until 2018 from 2.200 pts was presented at ESMO 2018. We present an update with data cut Q3/2023, including data from 8.936 pts recruited by 181 sites.
Results
Since 2022, 99% of nsq pts, and 97% of sq pts were tested with at least one test method at start of first-line. The respective test rates before 2020 (2020-TR) were 95% (nsq) and 78% (sq). In 2023 78% (nsq) and 62% (sq) of pts were tested by NGS (vs. 46% / 17% before 2020). Test rates for nsq pts in 2022 (vs. 2020-TR) for EGFR, ALK, ROS1, and BRAF were 83% (80%), 84% (78%), 84% (71%), and 81% (61%), respectively. Test rates for sq pts in 2022 (vs. 2020-TR) for EGFR, ALK, ROS1, and BRAF were 57% (30%), 58% (27%), 57% (23%), and 54% (23%), respectively. Test rates for PD-L1 increased to 86% in 2022/23 from 70% (nsq), and 67% (sq) before 2020. Current test rates for new clinical relevant markers (vs. 2020-TR) for nsq pts were 74% (31%) for RET, 77% (41%) for C-MET, and 77% (50%) for KRAS. Respective test rates for sq pts were 57% (6%) for RET, 58% (17%) for C-MET, and 55% (18%) for KRAS. For nsq pts for whom test results were available at time of analysis, an alteration in EGFR was detected in 16% (n=889), in ALK in 6% (n=327), in ROS-1 in 3% (n=156), in BRAF V600 in 2% (n=100), and RET fusions in 1% (n=30). For pts for whom test results were available at time of analysis, a C-MET exon 14 skipping alteration was detected in 2% (n=64, nsq), and 1% (n=4, sq), and a KRAS G12C alteration in 14% (n=611, nsq), and 2% (n=8, sq), and a TPS ≥50% was documented for 30% (n=1598, nsq) and 28% (n=380, sq) of pts.
Conclusions
CRISP presents current real life data on molecular testing from all treatment sectors in Germany. Test rates for markers with more recently available targeted treatment options reached similar levels as for earlier established markers.
Clinical trial identification
NCT02622581.
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGbmH.
Funding
Amgen Ltd., AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co.KG, Bristol Myers Squibb GmbH & Co., KGaA, Celgene GmbH, Daiichi Sankyo Deutschland GmbH, Gilead Sciences GmbH, GSK Research & Development Limited, Janssen-Cilag GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Regeneron GmbH, Roche Pharma AG, Takeda Pharma Vertrieb GmbH & Co.KG.
Disclosure
F. Griesinger: Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, AbbVie, Tesaro/GSK, Amgen, Sanofi, Daiichi Sankyo, BeiGene; Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, AbbVie, Siemens, Tesaro/GSK, Amgen, Sanofi, Daiichi Sankyo, BeiGene; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens, Amgen. W.E.E. Eberhardt: Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, Roche, Sanofi-Aventis, MSD, Amgen, Takeda, Boehringer Ingelheim, Novartis, Pfizer, Bayer, Eli Lilly; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Roche, Sanofi-Aventis, MSD, Amgen, Takeda, Boehringer Ingelheim, Novartis, Pfizer, Bayer, Eli Lilly; Financial Interests, Institutional, Funding: AstraZeneca. W. Weichert: Financial Interests, Personal, Advisory Board: Roche, MSD, AstraZeneca, Pfizer, Merck, Lilly, Boehringer Ingelheim, Novartis, Takeda, Amgen, Astellas, Janssen, BMS; Financial Interests, Personal, Speaker’s Bureau: Roche, MSD, AstraZeneca, Pfizer, Merck, Lilly, Boehringer Ingelheim, Novartis, Takeda, Amgen, Astellas, Janssen, BMS; Financial Interests, Institutional, Funding: Roche, MSD, BMS, Bruker. M. Sebastian: Financial Interests, Personal, Advisory Role: AstraZeneca, Amgen, Boehringer Ingelheim, Takeda, BMS, MSD, GSK, Merck-Serono, Novartis, Pfizer, Roche, Eli Lilly; Financial Interests, Personal, Invited Speaker: AstraZeneca, Amgen, Boehringer Ingelheim, Takeda, BMS, MSD, GSK, Merck-Serono, Novartis, Pfizer, Roche, Eli Lilly; Financial Interests, Institutional, Funding: AstraZeneca. M. Thomas: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BeiGene, BMS, Boehringer Ingelheim, Celgene, Chugai, Daiichi Sankyo, GSK, Janssen, Lilly, Merck/MSD, Roche, Takeda, Sanofi; Financial Interests, Institutional, Funding: AstraZeneca, BMS, Merck, Roche, Takeda; Financial Interests, Personal, Other, Refunding of Travel Cost: AstraZeneca, Boehringer Ingelheim, BMS, Daiichi Sankyo, Janssen, Lilly, Merck/MSD, Novartis, Pfizer, Roche, Sanofi, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1382P - Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
Presenter: Maurice Pérol
Session: Poster session 06
1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study
Presenter: Dongmei Lin
Session: Poster session 06
1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Yuki Sato
Session: Poster session 06
1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma
Presenter: Mariana Mancini
Session: Poster session 06
1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI
Presenter: Wei Xin Zhao
Session: Poster session 06
1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK
Presenter: Rubab Batool
Session: Poster session 06
1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
Presenter: Siddhartha Goutam
Session: Poster session 06
1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Presenter: Inès Duparc
Session: Poster session 06